The fixed-dose combination of sofosbuvir + velpatasvir (sold as Epclusa) has activity against all major strains, or genotypes, of hepatitis C virus (HCV). The combination of these drugs has been evaluated for possible and potential interactions with other drugs.
Here are recommendations from Epclusa manufacturer Gilead Sciences:
In people coinfected with HIV and HCV, the following drugs can be used:
What is clear from the drug interaction studies with Epclusa is that the anti-HIV drug efavirenz (Sustiva, Stocrin and in Atripla) must not be used because it can reduce absorption of velpatasvir by about 50%.
No loss of efficacy with oral contraceptives containing norgestimate/thinly estradiol should occur.
Sofosbuvir-velpatasvir does not appear to have significant interactions with cyclosporine (Neoral, Sandimmune) or tacrolimus (Advagraf, Prograf).
Complete details about drug interactions between sofosbuvir-velpatasvir and other medicines will be released in the future by Gilead.
Mogalian E, McNally J, Shen G, et al. Drug-drug interaction profile of sofosbuvir-velpatasvir fixed-dose combination. The International Liver Congress, 13-17 April 2017, Barcelona, Spain. Abstract FRI-168.
|Sofosbuvir + Velpatasvir (Epclusa) + Ribavirin for Retreatment|
|Sofosbuvir + Velpatasvir (Epclusa) in HIV Coinfection|
|Sofosbuvir + Velpatasvir (Epclusa) -- Improvements in Quality of Life, Energy and Emotional and Mental Health|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|